TRDA
Entrada Therapeutics Inc.
$5.37
-$0.05(-0.92%)
62
Overall
80
Value
45
Tech
--
Quality
Market Cap
$194.75M
Volume
226.91K
52W Range
$4.93 - $21.79
Target Price
$18.50
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | -- | -- | $129.0M | $210.8M | ||
| Total Revenue | -- | -- | $129.0M | $210.8M | ||
| GROSS PROFIT | ||||||
| Gross Profit | -- | -- | $129.0M | $210.8M | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $51.1M | $97.2M | $132.2M | $163.8M | ||
| Research & Development | $35.9M | $66.6M | $99.9M | $125.3M | ||
| Research Expense | $35.9M | $66.6M | $99.9M | $125.3M | ||
| Selling, General & Administrative | $15.2M | $30.6M | $32.3M | $38.5M | ||
| General & Administrative Expenses | $15.2M | $30.6M | $32.3M | $38.5M | ||
| Salaries & Wages | -- | -- | $13.1M | $17.9M | ||
| Depreciation & Amortization | $1.1M | $1.9M | $2.8M | $3.8M | ||
| Depreciation & Amortization | $1.1M | $1.9M | $2.8M | $3.8M | ||
| Other Operating Expenses | $6.0M | $8.8M | $16.4M | $15.5M | ||
| OPERATING INCOME | ||||||
| Operating income | $-51.1M | $-97.2M | $-3.2M | $47.0M | ||
| EBITDA | $-50.1M | $-95.4M | $14.9M | $70.3M | ||
| NON-OPERATING ITEMS | ||||||
| Net Non-Operating Interest Income/Expense | -- | $-2.6M | $-15.2M | -- | ||
| Other Income/Expense | $31.0K | $-2.6M | -- | -- | ||
| Other Special Charges | $-31.0K | $2.6M | -- | -- | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-51.2M | $-97.2M | $12.0M | $66.5M | ||
| Pre-Tax Income | $-51.2M | $-94.6M | $-3.2M | $47.0M | ||
| INCOME TAX | ||||||
| Tax Provision | -- | -- | $18.7M | $900.0K | ||
| NET INCOME | ||||||
| Net Income | $-51.2M | $-94.6M | $-6.7M | $65.6M | ||
| Net Income (Continuing Operations) | $-51.2M | $-94.6M | $-6.7M | $65.6M | ||
| Net Income (Discontinued Operations) | $-51.2M | $-94.6M | $-6.7M | $65.6M | ||
| Net Income (Common Stockholders) | $-51.2M | $-94.6M | $-6.7M | $65.6M | ||
| Normalized Income | -- | -- | -- | $46.5M | ||
| TOTALS | ||||||
| Total Expenses | $51.1M | $97.2M | $132.2M | $163.8M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $6.3M | $31.3M | $33.1M | $37.3M | ||
| Average Shares Outstanding (Diluted) | $6.3M | $31.3M | $33.1M | $39.0M | ||
| Shares Outstanding | $31.3M | $33.1M | $38.0M | $37.6M | ||
| Basic EPS | $-8.16 | $-3.02 | $-0.20 | $1.76 | ||
| Basic EPS (Continuing Operations) | $-8.16 | $-3.02 | $-0.20 | $1.76 | ||
| Diluted EPS | $-8.16 | $-3.02 | $-0.20 | $1.68 | ||
| Diluted EPS (Continuing Operations) | $-8.16 | $-3.02 | $-0.20 | $1.68 | ||
| OTHER METRICS | ||||||
| Other Gand A | $15.2M | $30.6M | $32.3M | $38.5M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TRDA | $5.37 | -0.9% | 226.91K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Entrada Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW